article thumbnail

Forge Biologics and Labcorp partner for gene therapies development

Pharmaceutical Technology

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.

article thumbnail

Gender Pay Gap Worsens Within European Life Sciences Industry

Pharma Marketing Network

The Healthcare Businesswoman’s Association Europe region released an update to its 2018 industry gender pay gap report that shows there is a clear increase in the pay gap between men and women in the life sciences sector in Europe. France and the U.K. reduced the pay gap to 4.8 percent and 5.1 Get the Full Report.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Outsourcing Peptide Synthesis: Preferred Choice of Drug Developers

Roots Analysis

Owing to the challenges involved in the synthesis process and demands of modern drug development, majority of drug developers in this domain prefer to outsource their development and manufacturing operations to peptide therapeutics contract API manufacturers as a strategic solution to streamline their research and peptide synthesis efforts.

article thumbnail

MilliporeSigma and ACD/Labs in collaboration to 'shape the future of analytical testing'

Outsourcing Pharma

Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA.

article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This venture also led me to identify a gap in the market for contract manufacturing of recombinant proteins.

article thumbnail

$82m investment in cell therapies for neurological diseases

Drug Discovery World

We are grateful for the support of a syndicate of leading life science investors and a team of industry veterans, including scientific co-founders Dr Howard Federoff and Dr Jeffrey Kordower, who see the promise in Kenai’s approach to treating central nervous system disorders,” said Nick Manusos, Chief Executive Officer of Kenai Therapeutics. “The

article thumbnail

Bespoke Gene Therapy Consortium Selects 8 Rare Diseases for Clinical Trial Portfolio

XTalks

The Bespoke Gene Therapy Consortium was jointly launched by the NIH and US Food and Drug Administration (FDA) in 2021 to help address common issues that gene therapy developers face. It included formulating a standardized therapeutic development model that would help accelerate clinical trial processes for new treatments.